Search

Antibody Drug Conjugates with Amatoxin Derivatives for Cancer Treatment

Vivasor, Inc. has been granted European Patent EP3471771A1 covering antibody drug conjugates using amatoxin derivatives as cytotoxic payloads for the treatment of cancer, with publication occurring on 15 April 2026. The patent application EP3471771 claims priority based on earlier filings and lists four named inventors: ZHU Tong, ZHANG Hong, KHASANOV Alisher, and CHEN Gang. The designation covers 32 European contracting states including Germany, France, the United Kingdom, Italy, Spain, the Netherlands, Sweden, and others.

Macrocyclic Compounds, SRC MET Inhibitor, Cancer Treatment

USPTO granted patent US12606571B2 to Turning Point Therapeutics, Inc. for macrocyclic compounds that inhibit SRC and MET and/or CSF1R, pharmaceutical compositions thereof, and methods of using such compounds to treat cancer. The patent contains 9 claims and was granted on April 21, 2026.

Roche EP4251614A1: N-Substituted Aniline Hepatitis B Treatment

The EPO has granted patent EP4251614A1 to F. Hoffmann-La Roche AG covering N-substituted 4-(5-phenyl-1,3,4-oxadiazol-2-yl)aniline compounds for the treatment and prophylaxis of hepatitis B virus infection. The patent, filed with four named inventors (LIN Xianfeng, YUN Hongying, ZHANG Bo, ZHENG Xiufang), carries IPC classifications spanning C07D chemical compounds and A61K/A61P pharmaceutical preparations. Designated states include all major European Patent Convention member states. This grant confers exclusive rights to Roche across EU member jurisdictions for the claimed HBV therapeutic applications.